期刊文献+

P53在膀胱移行细胞癌的表达及临床意义

P53 Gene Product Expressions and Their Clinical Significance in Transitional Cell Carcinoma of the Bladder
下载PDF
导出
摘要 目的探讨P53在膀胱移行细胞癌的表达与膀胱移行细胞癌生物学行为的关系及临床意义。方法采用免疫组化(SABC)检测62例膀胱移行细胞癌中P53的表达情况。结果P53表达阳性率均随着膀胱癌的病理分级、临床分期上升而升高,且有统计学意义(P<0.05),P53阳性者的复发率明显高于阴性表达者,且有统计学意义(P<0.05)。结果本研究显示,P53表达水平与膀胱移行细胞癌组织学分级、临床分期及复发密切相关,随着膀胱移行细胞癌分级的增高而显著增高,浸润性膀胱移行细胞癌(T2-T4期)表达水平高于表浅性膀胱移行细胞癌(Tis-T1期);复发性膀胱移行细胞癌的表达水平明显高于初发性膀胱移行细胞癌。结论P53检测能为判断膀胱移行细胞癌的恶性程度和复发提供依据。  Objective To investigate the expressions of P53 gene products and their relationship with neoplastic biological behavior in transitional cell carcinoma of the bladder and their clinical significance as well. Methods The expressions of P53 gene products of 62 patients with transitional cell carcinoma of the bladder were evaluated using immunohistological method(SABC). Results The rate of positive expression of P53 gene product increased with the increase of histological grade and clinical stage and there was statistical significance(P〈0.05).The rate of recurrence of patients P53 positively expressed was significantly higher than that of patients P53 negatively expressed and statistical significance was found as well(P〈0.05). Conclusion The essay demonstrated that P53 gene product expressions was associated with histological grade,clinical stage and recurrence of transitional cell carcinoma of the bladder. Their expressions increased significantly with the increase of histological grade. Their expressions in invasive transitional cell carcinoma of the bladder(T2-T4)were much higher than in superficial phenotype(Tis-T1).Their expressions in recurrent cases were higher than in the other cases. The essay suggested that P53 might be used as objective indicators of malignance and recurrence of transitional cell carcinoma of the bladder.
出处 《青岛医药卫生》 2007年第5期324-326,共3页 Qingdao Medical Journal
关键词 膀胱移行细胞癌 免疫化学 P53基因表达 Transitional cell carcinoma of the bladder Immunohistochemistry P53 gene expression
  • 相关文献

参考文献1

二级参考文献10

  • 1Simon KM.Design and conduct of clinical trials.In:Devita,Jr,VT. Hellman S,Kosenkerg SA.Cancer.Principles and Practice of Oncology. Vol1.Lippincott,Philadelphia,Third Edition,PP396-420.
  • 2Fakharzadch SS,Tursko SP,George DL.Tu-morigenic protential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.EMBO J,1991,10:1565.
  • 3Picksley SM,Vojtesek B,Sparks A,et al,Immunochemical analysis of the interaction of P53 with mdm2;fine mapping of the mdm2 binding site on P53 using synthetic peptides.Oncogene,1994.9:2523.
  • 4Leng P,Brown DR,Shivakumar CV,et al.Nterminal 130 amino acids of mdm2 are sufficient to inhibit P53-medlated transcriptional activation. Oncogene,1995,10:1275.
  • 5Barak Y,Gottlieb E,Juven-Gershon T,et al.Regulation of mdm2 expression by P53:alternative promoters produce transcripts with nonidentical translation protential.Genes & Development,1994,8:1739.
  • 6Haines DS,Landers JE,Engle LJ,et al.Physical and functional interaction between wild-type P53 and mdm2 proteins.Mol Cell Biol,1994,14:1171.
  • 7Lane DP.P53 guardian of the genoma.Nature,1992,358:15.
  • 8Oliner JD,Kinzler KW.Meltzer PS,et al.Amplification of a gene encoding a P53-associated protein in human sarcomas.Nature,1992,358:80.
  • 9Fujimoto K,Yameta Y,Orajima F,et al.Frequent association of P53 gene matation in invasive bladder cancer.Cancer Res,1992,52:1393.
  • 10Lianes P,Oriow I,Zhang IF,et al.Altered patterns of mdm2 and P53 expression in human bladder cancer.J Natl Cancer Inst,1994,86:1325.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部